2. Signaling Pathways
  3. Immunology/Inflammation
  4. PSMA

PSMA

Prostate-specific membrane antigen

PSMA is a transmembrane protein that anchores to the cell membrane through its transmembrane region and is mainly expressed in prostate epithelial cells but also exists in other tissues. PSMA exhibits glutamate-preferring carboxypeptidase activity that hydrolyzes polyglutamylated folic acid to release folic acid monomers. PSMA mediates the endocytosis on the cell surface. PSMA acts as an angiogenesis marker in cancer cells. PSMA can be used as a diagnostic marker for prostate cancer, and for detection of invasiveness and metastatic ability of the tumor[1].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10740
    CBP-1018
    		Ligand 99.21%
    CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer.
    CBP-1018
  • HY-P11261
    AAZTA-NI-PSMA-093
    AAZTA-NI-PSMA-093 is a bispecific agent targeting prostate-specific membrane antigen (PSMA) with an IC50 value for PSMA of 87.48 nM. AAZTA-NI-PSMA-093 has a PSMA targeting module and an oxygen-sensitivity module (hypoxia-sensitive NI-moiety). AAZTA-NI-PSMA-093 can utilize the PSMA targeting property as a "navigation system" to efficiently concentrate the entire molecule within prostate cancer cells, and once the cells are in an oxygen-deficient state, the molecule will irreversibly capture and remain in the oxygen-deficient cells, achieving "secondary enrichment". AAZTA-NI-PSMA-093 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu, and has high accumulation and rapid clearance characteristics in mouse models. AAZTA-NI-PSMA-093 can be used for the study of prostate cancer.
    AAZTA-NI-PSMA-093
  • HY-182240
    Cy5-ZW2-617
    		Ligand
    Cy5-ZW2-617 is a PSMA ligand with a IC50 of 4.39 nM. Cy5-ZW2-617 specifically binds to PSMA and is thereby internalized by PSMA-positive cells. Cy5-ZW2-617 shows uptake in PSMA-positive tumor cells and tumor xenografts in mice. Cy5-ZW2-617 can be used for the research of prostate cancer.
    Cy5-ZW2-617
  • HY-169336
    CQ-16
    CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
    CQ-16
  • HY-173476
    TcO-ABX474
    		Inhibitor
    TcO-ABX474 (TcO-5) is a potent prostate-specific membrane antigen (PSMA) inhibitor with a Kd value of 6.1 nM. TcO-ABX474 inhibits prostate cancer cell growth and metastasis. TcO-ABX474 is promising for research of prostate cancer.
    TcO-ABX474
  • HY-129615
    MIP-1072
    		Inhibitor
    MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer.
    MIP-1072
  • HY-177808
    A9g sodium
    		Inhibitor
    A9g sodium is an RNA aptamer that inhibits the enzymatic activity of prostate-specific membrane antigen (PSMA).
    A9g sodium
  • HY-P99554
    Topsalysin
    Topsalysin is a PSA-activated protoxin, a pore-forming protein (synthetic proaerolysin) fusion protein with human prostate-specific antigen. Topsalysin has tumor suppression effect in mice modle.
    Topsalysin
  • HY-164575B
    NH2-NODAGA hydrochloride
    NH2-NODAGA hydrochloride is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA hydrochloride can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA hydrochloride
  • HY-175229
    PSMA ligand 1
    		Ligand
    PSMA ligand 1 (Compound 1c) is a PSMA ligand with an IC50 of 26.74 nM. The [18F]-labeled PSMA ligand 1 can serve as a PSMA PET tracer and is used in research on the diagnosis of prostate cancer.
    PSMA ligand 1
  • HY-D3353
    PSMA-SulfoCy7
    		Ligand
    PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies.
    PSMA-SulfoCy7
  • HY-P11310
    PSMA-1-SMCC
    		Ligand 98.16%
    PSMA-1-SMCC is a selective binding agent targeting Prostate-Specific Membrane Antigen (PSMA). PSMA-1-SMCC is promising for research of targeted imaging for prostate cancer.
    PSMA-1-SMCC
  • HY-123733
    MIP-1095
    		Inhibitor
    MIP-1095 potently inhibits the glutamate carboxypeptidase activity of PSMA (Ki =0.24 nM).
    MIP-1095
  • HY-P991360
    MLN 591
    		Inhibitor
    MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research.
    MLN 591
  • HY-163196
    PSMA-IN-4
    		Inhibitor
    PSMA-IN-4 (compound 9) is a potent inhibitor of PSMA, with the IC50 value of 1.2 μM.
    PSMA-IN-4
  • HY-164575
    NH2-NODAGA
    NH2-NODAGA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA can react with diethyl squarate in 0.5M phosphate buffer to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA
  • HY-153130
    (S)-Zadavotide guraxetan
    (S)-Zadavotide guraxetan ((S)-PSMA I&T) is the S-isomer of EuK-Sub-kf-iodo-y-DOTAGA. (S)-Zadavotide guraxetan is a PSMA targeting compound.
    (S)-Zadavotide guraxetan
  • HY-P10743
    BQ7876
    BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC). BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7876
  • HY-P992094
    Capromab
    		Inhibitor
    Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer.
    Capromab
  • HY-179051
    PSMA ligand 3
    		Ligand
    PSMA ligand 3 is a PSMA-targeting ligand of Psa-AR (HY-179056). Psa-AR can be used for cancer research.
    PSMA ligand 3
Cat. No. Product Name / Synonyms Application Reactivity